Our Products
See our range of cfDNA products below.
Pre-Analytical
Ensuring successful cfDNA analysis is our focus
Every sample is precious and to get the most out of your sample when evaluating cfDNA it is really critical to have processed your samples correctly from blood collection through to extracted cfDNA. Learn more about our Cell3 Preserver blood tube and Cell3 Xtract kit below.
Prenatal Healthcare
Non-invasive prenatal testing requires sensitive, reproducible and easy to use products.
Nonacus continues to develop innovative products to meet these exacting standards including tests for fetal rhesus-D genotyping, fetal fraction quantitation and single gene disorder testing.
Oncology
Efficient workflow enables confident calling of all ctDNA mutations
Nonacus are working with some of the brightest scientists and clinicians by providing a validated complete workflow for liquid biopsy analysis. With the ultimate goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.
Who we are
Designed by scientists, for Scientists
We are formed of a committed group of biotechnology professionals with a combined 35 years experience in genomic healthcare. We understand the pressure on laboratories to deliver progress and our products are designed to get you there. Between us, we’ve got global experience of genomic healthcare from the NHS in the UK through to an international genome project.
What we stand for
True Innovation That Benefits Patients
We translate research into routine diagnostic tools that directly benefit patients and scientists. Our non-invasive cell free DNA solutions improve diagnostic accuracy as well as the patient’s experience. Our research & development team are constantly developing, validating and testing new cfDNA products.
Built For Labs That Do
We supply Universities with our cfDNA products to help them improve their understanding and research in non-invasive healthcare.
Leading hospitals have adopted our products to help improve patient care through the innovative use of cfDNA technology allowing for non-invasive diagnostics.
We partner with many leading laboratories to constantly innovate and push our products further.
Read Our Latest Insights
What’s in a name?
When Chris Sale and Lee Silcock founded Nonacus in 2015 they had one singular purpose- To develop non-invasive DNA tests that would change the way genomic diagnostics was done. Choosing a name that would reflect this mission wasn’t easy. Find out why they went with Nonacus.
Read More
Delivering the potential of cancer genomics to patients
This week Nonacus Ltd announced a partnership with Dante Labs and Cambridge Cancer Genomics which aims to build the most comprehensive and patient-centric tumour profiling service enabling improved cancer patient management, treatment and monitoring.
Read More
Nonacus wins Government grant to validate rapid sequencing based surveillance testing for COVID-19.
Nonacus was recently awarded an Innovate UK grant, to validate a novel, rapid method for sequencing respiratory viral genomes using nanopore sequencing. This method will provide more comprehensive information about the Sars-CoV-2 genome to support a post pandemic world and, with a respiratory viral panel in the pipeline, will provide surveillance of other respiratory diseases too. So, if your cough is not due to COVID-19, you will be able to find out which respiratory virus is causing it.
Read More